(Site 211) Meridian Clinical Research Trials

(Site 211) Meridian Clinical Research	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Essink, Brandon

NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting

8600

Naltrexone-Bupropion (NB) Combination, Placebo

Currax Pharmaceuticals

Obesity

01/29

07/29

ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed

4205

Europe, US

ABNCoV2, Comirnaty

Bavarian Nordic

COVID-19 Disease

03/23

10/23

NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Completed

7741

Europe, Canada, US, RoW

Investigational aQIVc, licensed QIV1, licensed QIV2

Seqirus

Influenza, Human

03/24

01/25

NCT06374394: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

Active, not recruiting

842

Europe, US

RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine

GlaxoSmithKline

Respiratory Syncytial Virus Infections

11/24

05/25

RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting

12000

Europe, Canada, Japan, US, RoW

RSVPreF3 OA vaccine

GlaxoSmithKline

Respiratory Syncytial Virus Infections

09/26

NCT06672939: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Recruiting

125

Europe, Japan, US, RoW

Orforglipron, LY3502970, Placebo

Eli Lilly and Company

Obesity, Overweight

02/27

03/27

ADVANCE, NCT06672549: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Recruiting

125

Europe, Japan, US, RoW

Orforglipron, LY3502970, Placebo

Eli Lilly and Company

Obesity, Overweight

02/27

03/27

NCT06151288: Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Completed

1/2

1015

31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine, PCV20, Prevnar 20™

Vaxcyte, Inc.

Pneumococcal Vaccines

07/24

NCT06680375: A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

Active, not recruiting

1/2

780

Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA, SARS-CoV-2 mRNA Dose 1, SARS-CoV-2 mRNA Dose 2, Licensed Flu Seasonal, Licensed COVID-19 mRNA, Placebo, Phase 2 selected Investigational Flu Seasonal/SARS-CoV-2 mRNA, Phase 2 selected SARS-CoV-2 mRNA

GlaxoSmithKline

COVID-19

05/25

11/25

NCT05089630: A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Active, not recruiting

1/2

333

Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine, Pentamer (high)/gB(med)/Adjuvant vaccine, Placebo (saline)

GlaxoSmithKline

Cytomegalovirus Infections

06/25

NCT04909021: Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Recruiting

Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose)

Meissa Vaccines, Inc.

Respiratory Syncytial Virus (RSV)

10/23

NCT05664334: Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

Completed

140

IVX-121, IVX-241, Placebo, MF59®

Icosavax, Inc.

Healthy

01/24

NCT05477186: Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

Completed

185

US, RoW

CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg), CV0501 (25 μg), CV0501 (50 μg), CV0501 (100 μg), CV0501 (200 μg)

GlaxoSmithKline

COVID-19, SARS-CoV-2

08/23

NCT06573281: A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

Active, not recruiting

210

Europe, US, RoW

Investigational RSV vaccine 1, Investigational RSV vaccine 2, Investigational RSV vaccine 3, Investigational RSV vaccine 4, Investigational RSV vaccine 5, Investigational RSV vaccine 6, Placebo

GlaxoSmithKline

Respiratory Syncytial Virus Infections

08/26

NCT03569514: Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax

Not yet recruiting

N/A

AIGIV, ANTHRASIL®

Emergent BioSolutions, Centers for Disease Control and Prevention, Department of Health and Human Services

Anthrax

07/26

NCT03569553: A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

Not yet recruiting

N/A

100

AIGIV, ANTHRASIL®

Emergent BioSolutions, Centers for Disease Control and Prevention, Department of Health and Human Services

Inhalational Anthrax

07/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Essink, Brandon

NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting

8600

Naltrexone-Bupropion (NB) Combination, Placebo

Currax Pharmaceuticals

Obesity

01/29

07/29

ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed

4205

Europe, US

ABNCoV2, Comirnaty

Bavarian Nordic

COVID-19 Disease

03/23

10/23

NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Completed

7741

Europe, Canada, US, RoW

Investigational aQIVc, licensed QIV1, licensed QIV2

Seqirus

Influenza, Human

03/24

01/25

Active, not recruiting

842

Europe, US

RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine

GlaxoSmithKline

Respiratory Syncytial Virus Infections

11/24

05/25

Recruiting

12000

Europe, Canada, Japan, US, RoW

RSVPreF3 OA vaccine

GlaxoSmithKline

Respiratory Syncytial Virus Infections

09/26

NCT06672939: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Recruiting

125

Europe, Japan, US, RoW

Orforglipron, LY3502970, Placebo

Eli Lilly and Company

Obesity, Overweight

02/27

03/27

ADVANCE, NCT06672549: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Recruiting

125

Europe, Japan, US, RoW

Orforglipron, LY3502970, Placebo

Eli Lilly and Company

Obesity, Overweight

02/27

03/27

NCT06151288: Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Completed

1/2

1015

31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine, PCV20, Prevnar 20™

Vaxcyte, Inc.

Pneumococcal Vaccines

07/24

NCT06680375: A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

Active, not recruiting

1/2

780

GlaxoSmithKline

COVID-19

05/25

11/25

NCT05089630: A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Active, not recruiting

1/2

333

Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine, Pentamer (high)/gB(med)/Adjuvant vaccine, Placebo (saline)

GlaxoSmithKline

Cytomegalovirus Infections

06/25

NCT04909021: Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Recruiting

Meissa Vaccines, Inc.

Respiratory Syncytial Virus (RSV)

10/23

NCT05664334: Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

Completed

140

IVX-121, IVX-241, Placebo, MF59®

Icosavax, Inc.

Healthy

01/24

NCT05477186: Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

Completed

185

US, RoW

CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg), CV0501 (25 μg), CV0501 (50 μg), CV0501 (100 μg), CV0501 (200 μg)

GlaxoSmithKline

COVID-19, SARS-CoV-2

08/23

NCT06573281: A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

Active, not recruiting

210

Europe, US, RoW

Investigational RSV vaccine 1, Investigational RSV vaccine 2, Investigational RSV vaccine 3, Investigational RSV vaccine 4, Investigational RSV vaccine 5, Investigational RSV vaccine 6, Placebo

GlaxoSmithKline

Respiratory Syncytial Virus Infections

08/26

NCT03569514: Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax

Not yet recruiting

N/A

AIGIV, ANTHRASIL®

Emergent BioSolutions, Centers for Disease Control and Prevention, Department of Health and Human Services

Anthrax

07/26

NCT03569553: A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

Not yet recruiting

N/A

100

AIGIV, ANTHRASIL®

Emergent BioSolutions, Centers for Disease Control and Prevention, Department of Health and Human Services

Inhalational Anthrax

07/26



	Diseases Companies Products Productz Mechanisms of Action Sites